<DOC>
	<DOCNO>NCT00513955</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy , cyclophosphamide , doxorubicin , vincristine , prednisolone , work different way stop growth cancer cell , either kill cell stop dividing . Bortezomib may stop growth cancer cell block enzymes need cell growth . Giving combination chemotherapy together bortezomib may kill cancer cell . It yet know whether combination chemotherapy effective without bortezomib treat mantle cell lymphoma . PURPOSE : This randomized phase II trial study combination chemotherapy bortezomib see well work compare combination chemotherapy alone treat patient relapsed refractory mantle cell lymphoma . Combination chemotherapy alone ( Arm I ) discontinue April 2012 recommendation DMC .</brief_summary>
	<brief_title>Combination Chemotherapy With Without Bortezomib Treating Patients With Relapsed Refractory Mantle Cell Lymphoma</brief_title>
	<detailed_description>OBJECTIVES : Primary - To evaluate rate overall response ( complete response [ CR ] , CR unconfirmed [ CRu ] , partial response ) . Secondary - To evaluate rate CR CRu . - To determine median time progression . - To determine median overall survival . - To evaluate toxicity tolerability . - To compare response treatment regimen first line therapy . - To compare quality life . OUTLINE : This randomize , open-label , parallel group , multicenter study . Patients randomize 1 2 treatment arm . - Arm I ( CHOP ) : Patients receive doxorubicin hydrochloride IV , cyclophosphamide IV , vincristine IV day 1 oral prednisolone day 1-5 . Arm I discontinue April 2012 recommendation DMC . - Arm II ( CHOP bortezomib ) : Patients receive bortezomib IV 3-5 second day 1 8 ; doxorubicin hydrochloride IV , cyclophosphamide IV , vincristine IV day 1 ; oral prednisolone day 1-5 . In arm , treatment repeat every 21 day 8 course absence disease progression unacceptable toxicity . Patients complete quality life questionnaire baseline , prior treatment course , 30 day completion treatment . After completion study treatment , patient follow 30 day every 12 week thereafter .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Mantle-Cell</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Bortezomib</mesh_term>
	<mesh_term>Vincristine</mesh_term>
	<mesh_term>Prednisolone</mesh_term>
	<mesh_term>Methylprednisolone Hemisuccinate</mesh_term>
	<mesh_term>Prednisolone acetate</mesh_term>
	<mesh_term>Methylprednisolone acetate</mesh_term>
	<mesh_term>Methylprednisolone</mesh_term>
	<mesh_term>Prednisolone hemisuccinate</mesh_term>
	<mesh_term>Prednisolone phosphate</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Diagnosis mantle cell lymphoma ( MCL ) Expression cyclin D1 evidence ( 11 ; 14 ) translocation cytogenetics , FISH , polymerase chain reaction Refractory relapse progress first line antineoplastic therapy Measurable disease PATIENT CHARACTERISTICS : Inclusion criterion : Karnofsky performance status ( PS ) 50100 % OR ECOG PS 02 ANC ≥ 1,000/mm³ ( related lymphoma ) Platelet count ≥ 30,000/mm³ AST ALT ≤ 3 time upper limit normal ( ULN ) Total bilirubin ≤ 2 time ULN Creatinine clearance ≥ 20 mL/min Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception Exclusion criterion : Known serological positivity HBV , HCV , HIV History allergic reaction attributable compound contain boron mannitol Diagnosed treated malignancy MCL within past 5 year except completely resect basal cell squamous cell carcinoma skin situ malignancy Active systemic infection require treatment Serious medical psychiatric illness would preclude study participation PRIOR CONCURRENT THERAPY : Inclusion criterion : Toxic effect prior therapy surgery must resolve ≤ grade 2 Prior splenectomy localize radiotherapy allow Any prior chemotherapy regimen allow Chemotherapy may give combination rituximab Concurrent enrollment nontreatment study allow , provide interfere participation study Exclusion criterion : Prior bortezomib Antineoplastic therapy within past 3 week Nitrosoureas within past 6 week Rituximab , alemtuzumab ( Campath® ) , unconjugated therapeutic antibody within past 4 week Radiotherapy within past 3 week Major surgery within past 2 week Concurrent investigational agent</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2014</verification_date>
	<keyword>recurrent mantle cell lymphoma</keyword>
</DOC>